Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Physiomics (PYC) by Steve Moore in ShareProphets
- Avoid Pinewood Technologies Group (PINE) by Steve Moore in ShareProphets
- Underweight HGCapital Trust (HGT) by JP Morgan
- Avoid Beeks Financial Cloud Group (BKS) by Steve Moore in ShareProphets
- Buy Helios Towers (HTWS) by Bank of America
- Buy Barclays (BARC) by Bank of America
- Add AstraZeneca (AZN) by Simon Watkins in The Motley Fool
- Buy NATWEST GROUP (NWG) by Simon Watkins in The Motley Fool
- Hold InterContinental Hotels Group (IHG) by Peel Hunt
- Hold Ecora Resources (ECOR) by Peel Hunt
- Buy Applied Nutrition (APN) by Berenberg
- Hold Unilever (ULVR) by HSBC
- Neutral Airtel Africa (AAF) by Goldman Sachs
- Overweight Glanbia (CDI) (GLB) by Barclays
- Neutral AIB Group (CDI) (AIBG) by Goldman Sachs
- Hold GSK (GSK) by Berenberg
- Equal Weight Schroders (SDR) by Morgan Stanley
- Buy SSP Group (SSPG) by UBS
- Buy RS Group (RS1) by John Ficenec in The Times - Tempus
- Avoid Celebrus Technologies (CLBS) by Steve Moore in ShareProphets
AstraZeneca (AZN) Share Price
Health Care Sector
NOTE: This is based on 1,258 open tips for AstraZeneca (AZN)
| Latest Bid : 15,484.00p | Latest Ask : 15,488.00p |
| High Today : 15,510.00p | Low Today : 15,174.00p |
| This Years High : 15,510.00p | This Years Low : 9,667.00p |
| Volume : 536,470 | MKT Cap : £240591M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
AstraZeneca (AZN) Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.AstraZeneca (AZN) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Deutsche Bank | Premium Only | 2025-10-16 07:14:00 16/10/2025 | -24.61% |
| Overweight | JP Morgan | Premium Only | 2025-10-13 13:31:00 13/10/2025 | 22.90% |
| Buy | Shore Capital | Premium Only | 2025-10-07 15:46:00 07/10/2025 | 14.97% |
| Buy | Goldman Sachs | Premium Only | 2025-10-02 06:51:00 02/10/2025 | 19.31% |
| Buy | Goldman Sachs | Premium Only | 2025-09-17 06:56:00 17/09/2025 | 32.42% |
AstraZeneca (AZN) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 15,484.00p | Latest Ask : 15,488.00p |
| High Today : 15,510.00p | Low Today : 15,174.00p |
| This Years High : 15,510.00p | This Years Low : 9,667.00p |
| Volume : 536,470 | MKT Cap : £240591M |
AstraZeneca Overview
A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest AstraZeneca Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Deutsche Bank | Premium Only | 2025-10-16 07:14:00 16/10/2025 | -24.61% |
| Overweight | JP Morgan | Premium Only | 2025-10-13 13:31:00 13/10/2025 | 22.90% |
| Buy | Shore Capital | Premium Only | 2025-10-07 15:46:00 07/10/2025 | 14.97% |
| Buy | Goldman Sachs | Premium Only | 2025-10-02 06:51:00 02/10/2025 | 19.31% |
| Buy | Goldman Sachs | Premium Only | 2025-09-17 06:56:00 17/09/2025 | 32.42% |